Dramatic Effect of Oral CSF-1R Kinase Inhibitor on Retinal Microglia Revealed by In Vivo Scanning Laser Ophthalmoscopy

This report provides sound evidence that the small molecule pharmaceutical PLX5622, a highly selective CSF-1R kinase inhibitor, crosses the blood–retina barrier and suppresses microglia activity. Members of this class of drug are in advanced clinical development stages and may represent a novel appr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebneter, Andreas, Kokona, Despina, Jovanovic, Joël, Zinkernagel, Martin S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2017
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5407246/
https://www.ncbi.nlm.nih.gov/pubmed/28458957
http://dx.doi.org/10.1167/tvst.6.2.10
Descripción
Sumario:This report provides sound evidence that the small molecule pharmaceutical PLX5622, a highly selective CSF-1R kinase inhibitor, crosses the blood–retina barrier and suppresses microglia activity. Members of this class of drug are in advanced clinical development stages and may represent a novel approach to modulate ocular inflammatory processes.

Ejemplares similares